Cargando…
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
PURPOSE: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal canc...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881102/ https://www.ncbi.nlm.nih.gov/pubmed/31557064 http://dx.doi.org/10.1200/JCO.18.02309 |
_version_ | 1783473882544472064 |
---|---|
author | Deng, Yanhong Chi, Pan Lan, Ping Wang, Lei Chen, Weiqing Cui, Long Chen, Daoda Cao, Jie Wei, Hongbo Peng, Xiang Huang, Zonghai Cai, Guanfu Zhao, Ren Huang, Zhongcheng Xu, Lin Zhou, Hongfeng Wei, Yisheng Zhang, Hao Zheng, Jian Huang, Yan Zhou, Zhiyang Cai, Yue Kang, Liang Huang, Meijin Wu, Xiaojian Peng, Junsheng Ren, Donglin Wang, Jianping |
author_facet | Deng, Yanhong Chi, Pan Lan, Ping Wang, Lei Chen, Weiqing Cui, Long Chen, Daoda Cao, Jie Wei, Hongbo Peng, Xiang Huang, Zonghai Cai, Guanfu Zhao, Ren Huang, Zhongcheng Xu, Lin Zhou, Hongfeng Wei, Yisheng Zhang, Hao Zheng, Jian Huang, Yan Zhou, Zhiyang Cai, Yue Kang, Liang Huang, Meijin Wu, Xiaojian Peng, Junsheng Ren, Donglin Wang, Jianping |
author_sort | Deng, Yanhong |
collection | PubMed |
description | PURPOSE: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results. METHODS: Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m(2), fluorouracil 400 mg/m(2), and fluorouracil 2.4 g/m(2) over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m(2) on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS). RESULTS: In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% (P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% (P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% (P = .971 by log-rank test), respectively. CONCLUSION: mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens. |
format | Online Article Text |
id | pubmed-6881102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-68811022020-12-01 Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial Deng, Yanhong Chi, Pan Lan, Ping Wang, Lei Chen, Weiqing Cui, Long Chen, Daoda Cao, Jie Wei, Hongbo Peng, Xiang Huang, Zonghai Cai, Guanfu Zhao, Ren Huang, Zhongcheng Xu, Lin Zhou, Hongfeng Wei, Yisheng Zhang, Hao Zheng, Jian Huang, Yan Zhou, Zhiyang Cai, Yue Kang, Liang Huang, Meijin Wu, Xiaojian Peng, Junsheng Ren, Donglin Wang, Jianping J Clin Oncol ORIGINAL REPORTS PURPOSE: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results. METHODS: Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m(2), fluorouracil 400 mg/m(2), and fluorouracil 2.4 g/m(2) over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m(2) on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS). RESULTS: In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% (P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% (P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% (P = .971 by log-rank test), respectively. CONCLUSION: mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens. American Society of Clinical Oncology 2019-12-01 2019-09-26 /pmc/articles/PMC6881102/ /pubmed/31557064 http://dx.doi.org/10.1200/JCO.18.02309 Text en © 2019 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | ORIGINAL REPORTS Deng, Yanhong Chi, Pan Lan, Ping Wang, Lei Chen, Weiqing Cui, Long Chen, Daoda Cao, Jie Wei, Hongbo Peng, Xiang Huang, Zonghai Cai, Guanfu Zhao, Ren Huang, Zhongcheng Xu, Lin Zhou, Hongfeng Wei, Yisheng Zhang, Hao Zheng, Jian Huang, Yan Zhou, Zhiyang Cai, Yue Kang, Liang Huang, Meijin Wu, Xiaojian Peng, Junsheng Ren, Donglin Wang, Jianping Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial |
title | Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial |
title_full | Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial |
title_fullStr | Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial |
title_full_unstemmed | Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial |
title_short | Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial |
title_sort | neoadjuvant modified folfox6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the chinese fowarc trial |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881102/ https://www.ncbi.nlm.nih.gov/pubmed/31557064 http://dx.doi.org/10.1200/JCO.18.02309 |
work_keys_str_mv | AT dengyanhong neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT chipan neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT lanping neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT wanglei neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT chenweiqing neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT cuilong neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT chendaoda neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT caojie neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT weihongbo neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT pengxiang neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT huangzonghai neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT caiguanfu neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT zhaoren neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT huangzhongcheng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT xulin neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT zhouhongfeng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT weiyisheng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT zhanghao neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT zhengjian neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT huangyan neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT zhouzhiyang neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT caiyue neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT kangliang neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT huangmeijin neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT wuxiaojian neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT pengjunsheng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT rendonglin neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial AT wangjianping neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial |